Abstract-The objective of this study was to lay a foundation for future cost-benefit analyses evaluating the public health impact of treatment and screening protocols for prostate cancer. Specifically we wanted to define the relative impact on cancer-specific mortality rates of the individual epidemiological components: pathological incidences by age groups, cancer progression rates, and the effect of competing causes of death, assuming expectant management (i.e. no definitive treatment). A biological model of prostate cancer incidence and progression was converted into a standard Markov tree where competing causes of death could occur. Weighted averages of progression rates were obtained from clinical studies. Separate cohorts of 30 year old black and white men were followed for 50 years. The model yielded cancer-specific mortality rates, overall mortality rates, and pathologic prevalences for both white and black males, consistent with the literature. Sensitivity analyses showed that of all the parameters studied, the pathological incidence of cancer in men under 50 years of age had the greatest impact on the cancer-specific mortality rates. Also important was the annual probability of progression of Al lesions. However the other parameters including pathological incidence in older males, and progression from locally-extensive to metastatic lesions had much smaller effects. In summary, this model correlates the clinical literature with the epidemiology of prostate cancer and can be used for further decision analyses. We recommend that future research be done to more precisely quantify the pathological incidence of prostate cancer in men under 5&60 years of age. More certainty is also needed before generalizing the results of relatively small Al series to millions of men, since Al progression rates critically affect the eventual cancer-specific mortality. Enough uncertainty remains at this point however, that we cannot advocate widespread screening for prostate cancer until its merit be demonstrated either by the definitive long term study, or by examination of costs and quality-of-life-adjusted benefits.
INTRODUCTION
Prostate cancer provokes controversies in diagnosis, management, and early detection because its natural history is poorly understood [l] . Newer screening modalities and treatment protocols could potentially affect millions of Amer- Natural history Decision analyican men at a cost of billions of dollars [2] since it is the most common non-skin carcinoma [3] in males.
We have developed a Markov model [4] to simulate the clinical epidemiology of prostate cancer. This model starts with the pathological incidence in various ages and follows the cancer progression through the various stages until death occurs either from prostate cancer or from other competing causes. We derived the progression rates from familiar studies in the literature-flawed though they be, since various clinical papers have and will continue to be used as support or rejection for recommendations for the ideal treatment or mode of screening for prostate cancer.
Undoubtedly individual tumors can progress rapidly [5] , and the course of individual patients varies, but these may not accurately represent the larger population with prostate cancer. It is possible that a subset of patients, as described in a particular clinical study, may have a progression rate so large that if it were representative of all patients within a given stage, many more deaths due to prostate cancer would occur than seems possible given the current annual mortality figures. By the same token, if one believes a low progression rate, why is it that many men do progress and die? An epidemiological model such as ours can help reconcile these differences by estimating what an average progression rate of a stage would have to be in order to obtain realistic mortality figures. It is also possible via sensitivity analyses, to determine which age-specific incidences or stage progression rates would most affect the cancerspecific mortality of the population. This information could then be used for further cost benefit analyses, and to help design further clinical studies. Although we cannot yet use this model to determine the merits of screening, we believe the model needs to be presented now in its current form to relate the complex prostate literature to the actual public health problem of prostate cancer.
Before we describe the methodology used in the development of the model, we want to summarize some of the problems with the prostate literature. These flaws certainly weaken our model and any model based on these studies, yet they also underscore the need for such a model to help reconcile the apparent contradictions. Strongly held opinions stem from publications of small series of treated patients, the use of non-comparable historical controls [6] , differences in treatment settings (referral centers vs community hospitals) [7] , definitions of progression/treatment failures, and methods and duration of follow-up [6, 8] . Another important basis for the controversies is the effect of competing causes of death. The prevalence of prostate cancer is highest in older men [9] , most of whom die of other causes [6] , given the relatively smaller cancer-specific mortality rates reported by the Surveillance, Epidemiology, and , End Results (SEER) Program [lo] , shown in our Table 1 . It is also difficult to compare results from one paper to the next, since similar patients may be staged differently [ll, 121. Donohue compiled several series and found that the following clinical stages had the corresponding mean fractions of metastatic lymph node involvement found post-operatively [ 121: Al 0.02, A2 0.19, Bl 0.11, B2 0.29, B 0.22, C 0.46. To make matters even more confusing, even within the same stage, the extent of capsular perforation [8, , and the degree of tumor differentiation [16] can affect the prognosis. Faced with the clinical literature so huge and flawed, one may well choose a nihilistic approach which rejects the literature and waits for the definitive prospectively, randomized, controlled study of screened vs non-screened men. This may take time given the multiple choices of therapy and the rapid development of new screening tools. Furthermore, the older studies in the literature will continue to be cited to support a given treatment or approach. We have chosen to be neither nihilistic or naive, and have tried a pragmatic approach: can we somehow develop a model that refers to the literature, and make some assumptions with the goal of better understanding the public health problem of prostate cancer? METHODS Papers were identified using Paper Chase and the bibliographies were reviewed. 
ClassiJication system used

Formulas for progression rates and probabilities
Many papers reported their data differently. To standardize the measurements, we converted information into standard units: annual mortality rate, annual rate of formation of distant metastases, and annual rate of becoming locally extensive. We distinguished the site where progression or treatment failure was first noticed, either local progression to a C lesion or distant progression to a D2 lesion. For example if an A2 lesion became a C lesion within a 5 year period and later became a D2 lesion at year 10, we would count it as first progressing to a C lesion (and not double-count it as a D2). If on the other hand the first sign of progression was a bony metastasis, then we considered it as first progressing distantly to D2 and not to stage C. disease specific mortality rate = (crude rate) -(expected rate)
The derived rates were then converted into annual probabilities by using [25]:
where r is the rate (of mortality, or of local progression or of distant progression) and t is the time in which an event will occur, which is one year in our model.
Derivation of probability of developing prostate cancer
We used the estimated pathological prevalence of prostate cancer from a graph of prevalence vs age by Carter [9] . This paper was chosen since it was a compilation from the literature of 5250 autopsies with careful "step-section" technique. The indicated ages represent the beginning of 10 year intervals [H. B. Carter, personal communication] . From that graph we defined a curve using the statistical software package Systat (Wilkinson, Leland. SYSTAT: The System for Statistics. Evanston, IL: SYSTAT, Inc.; 1990), and estimated the pathological incidence as the difference in prevalence per 100,000 males over a 5 year interval, plus the deaths due to prostate cancer as reported in the SEER study [lo] , shown in Table 1 . The derived incidence rates were converted into annual probabilities of developing prostate cancer at a given age, then adjusted for use in the baseline analysis in order to yield the prevalences in Fig. 6 .
Clinical Studies (Tables 3 to 10)
Studies within similar stages were combined in order to calculate "weighted averages". We viewed these derived numbers as only rough estimates, since we are not confident of how similar these groupings are, given the problems inherent in the prostate literature. For this reason, we did not feel further statistical analyses on variance was meaningful. The American College of Surgeons (ACS) series [7] was not included in the calculations of the "weighted averages" since it was so much larger than the other papers, and since many of its 20,661 clinically-staged patients received treatment. (The treatment given could theoretically lower the mortality rates compared to untreated patients, but clinical staging means there was probably inclusion of patients with positive lymph nodes which might raise the expected mortality rates.) Although our focus was on untreated (or delayed, or non-curatively treated) patients, we listed some series of treated patients . pAlA probability of an Al lesion progressing to an A2 lesion in one year. This is also assumed to be equal to the probability of progression to stage B. pBC, pBD1 probability of B lesions progressing to C or Dl lesions. pCD1, probability of progression from C to Dl. pDlD2, progression from Dl to D2. pDIE progression from D2 to death of prostate cancer. The baseline fraction of 0.17 is the proportion of the original cohort that died of prostate cancer at age 75. The "Sensitivity Analysis Fraction" is the proportion of the original cohort dying of prostate cancer that resulted from substituting the indicated sensitivity analysis value in place of the parameter's baseline value. See text for the definition of the "Sensitivity Index". to give "best scenario" rates. We assumed all histological cancers are biologically active and grow and progress with time. This is debatable since there are two possible ways to explain the discrepancy between the large number of histologic adenocarcinomas and the relatively smaller number of clinically important tumors [9] . The first is that all histological cancers will eventually grow into clinically significant tumors [69] , while the second assumes that all histological cancers need further transformation before becoming active [9] . In our model, we initially chose the first theory because it required fewer assumptions and estimates. We could have constructed the model by having WELL patients first enter a preliminary stage in which cancer could be diagnosed histologically but remain latent for a while before entering the A 1, A2, B, etc. cascade. To do this however, would require the ability (not currently available) of knowing which autopsy cancers are clinically active [9] . Nevertheless, in order for the model to eventually yield higher cancer-specific mortality rates for blacks compared to whites, the cancer progression rates might have to be different between whites and blacks-supporting the "multi-step" theory [9] . This point will be addressed later in more detail in the Discussion. We assumed stage A2 and B lesions are biologically-equivalent lesions. This is based on the similar mortality rates from the American College of Surgeons paper [7] , the similar incidence of positive lymph nodes in clinical A2 and B lesions [12] , morphologic data [70] , and levels of prostate specific antigen in A2 and Bl lesions [71] . With this assumption, we grouped the table values for A2 and B, which yielded a weighted annual transitional rate for each to C of 0.068, and to D2 0.028. We assumed that the progression rates per stage are the same regardless of the age of the patient although this has been debated. Some have proposed a similar prognosis regardless of age [72, 73, 74] , others have reported better corrected survival in younger patients [75] , and still others have reported a poorer prognosis in the younger age groups [76] . We assumed the progression rates used in the model are for a homogenous group of the earliest lesions in a given pathological stage. 7. We assumed the autopsy prevalence of cancer is the same for blacks and whites [77] . 8. We assumed no one would be spontaneously "cured" of prostate cancer.
The 'gold standards"
We defined the "standards" against which to measure our model as: (1) [4] . To arrive at these, we started with the weighted averages from the tables and inserted them in subtrees of the stages where progression to death could occur without the interference of non-cancer deaths.
To model the overall public health impact of prostate cancer, we studied an imaginary cohort of 30 year old men for 50 years. Whites and blacks were studied separately because of the racial differences in mortality rates, both cancerspecific [lo] and overall [78] . In the course of the following 12 months, some die of causes other than prostate cancer, some develop histological evidence of prostate cancer (and enter the Al state), but most remain in the WELL state. At the start of the second year, those in the WELL state again face the probabilities of death from other causes, of developing A 1 cancer, or remaining alive and free of cancer. Those who start the second year in the A 1 state face the probability of progressing to A2 or B states, or remaining alive in the A 1 state, or dying from other causes (with evidence of prostate cancer at autopsy). With time the WELL state gets smaller and only the DEAD states get progressively larger. The various cancer states have men entering and leaving them each year.
Parameters studied
Using the model we derived mortality rates for the individual stages using the logarithmic transformation formula. When we studied competing causes of death we defined the mortality rates as the change in the number of deaths in 5 year intervals divided by the fraction alive at the end of the interval. To derive prevalence in the model we used the fraction alive with cancer at a given age divided by the total fraction still alive at that point. This gave a similar curve to the change in the number of deaths of those with cancer over a 10 year interval divided by the total number of deaths in that same period plotted against the midpoint of the interval.
Statistical studies and "sensitivity index"
To compare mortality curves generated by the model and the SEER [IO] and Census Bureau [78] data, we used the software package Systat to calculate the Spearman correlation coefficients. Many sensitivity analyses [82] were performed. In order to show how much an individual parameter affected the cancer-specific mortality rates, we defined a "sensitivity index". This was derived by taking the difference in the fraction of the original cohort dead of cancer at age 75 (as determined by the parameter of concern's baseline and sensitivity analysis value), divided by the change in the parameter's baseline value and that used in the particular sensitivity analysis. This means that a parameter whose "sensitivity index" was high would affect the cancer-specific mortality more than a parameter whose sensitivity index was low. Table 2 ). A set of baseline values was determined, starting with a prevalence of prostate cancer in 30 years old of 0.0005 that yielded results compatible with the "gold standards" (Figs 2 to 6 ). Using a value of 0.015 for the annual probability of an Al lesion becoming an A2 lesion to 1 year in a white male Tp A 1 A2(w)], the Spearman correlation coefficient with the SEER [lo] white mortality rates was 0.9812 (for ages 35-80). The Spearman correlation coefficient was 1.000 for the overall mortality rate of the model and the Census Bureau A large number of sensitivity analyses were done for the cohort analysis as well as for the individual stages (Table 2 , Figs 2 to 5). Not surprisingly, the incidences of cancer in the younger years had the highest sensitivity indices and so greatly affected the cancer-specific mortality rates. The annual probability of an Al lesion progressing to an A2 (or B) lesion in the following year (pAlA and pAlB) also had an important effect. However, the progression rates from A2, B, and D2 lesions (pA2C, pBC, pA2D1, pBD1, pDIE) had smaller effects. The smallest sensitivity indices were for the transitional probabilities of progression from C and Table 2 . For whites the value of pAlA2(w) and pAlB(w) was 0.02; for blacks pAlAZ(b) and pAlB(b) was 0.03.
RESULTS
(See
Dl lesions (pCD1, pDlD2), meaning these DISCUSSION parameters affect cancer-specific mortality of Our model yielded mortality rates consistent the population only slightly. Figure 5 displays with the SEER [lo] and Census Bureau [78] the effects on the cancer-specific mortality when data, differentiated the large number of patients different incidence values were used in the dying with prostate cancer as opposed to those model. Generally speaking, if no additional dying of cancer, and gave literature-consistent cases of histological prostate cancer were to fractions of lymph node positivity in clinical develop beyond a certain age, the cancer-specific stages A2, B and C [ 121. Additionally our model mortality would not change until 5-10 years showed a larger proportion of advanced lesions afterwards.
in blacks compared to whites, and in older [60, 77] . We will discuss the implications of this model but will first point out the potential weaknesses of this paper.
The assumptions and reasoning are clearly stated and can be supported or criticized directly [82] . We made use of the clinical literature with all its flaws, so the transitional probabilities are certainly open to question. The literature gives widely-varying rates for most of the clinical stages. These can be explained by the problems mentioned in the introduction as well as: broad confidence limits even within a single paper (for example [29] ), some selection bias (e.g. the predominance of well-differentiated tumors in Johansson's series [6, 29] and the entry criteria for Whitmore's series [41, 831) . Our calculations could also be flawed due to difficulties translating data into specific fractions of "not becoming C", "not becoming D2", and the time frame of these events. Our response to these criticisms is that our baseline numbers taken together yield results compatible to those standards-also flawed-available. Yet the sensitivity analyses showed that when competing causes of death are considered, a wide range of values for most of the parameters used in the model will yield similar cancer-specific mortality. This suggests that debate in areas concerning these low-sensitivity parameters, for example the best. means of treating a C lesion, will have less of an effect on the male population's cancer-specific mortality. This is not the case however with those parameters with the higher sensitivity indices: the pathological incidences in younger men, and the progression probability of Al lesions as a group (pAlA and pAlB). These parameters greatly impact the cancer-specific mortality and do deserve further study and debate.
Since the pathologic incidences are so sensitive, a potential criticism of this model is its use of primarily one paper [9] for the derivation of the pathologic prevalences and incidences. Certainly there is a wide range of values reported for these, as shown by Stamey [80] . We used the Carter paper [9] because it was a compilation of 5250 autopsies from several papers concerning the population studied in our model-males in the United States-from which a smoothed curve of prevalence per age group was constructed. We felt this derived curve gave us information not found in other autopsy series: a means to minimize the effects of small sample sizes and variations in pathologic technique [80] , as well as to project cancer prevalence in the younger age groups subject to statistical error [76] . The Carter paper was therefore useful for a model such as ours whose objective was to define those parameters with the largest impact (i.e. highest sensitivity indices) on prostate cancer-specific mortality rates. However, caution is needed when using these values for determination of public policy due to their extreme sensitivity. Practically speaking, we urge future and more precise autopsy data, which may well decide the appropriateness of mass screening. An additional practical insight from the model is the demonstration of the lag time between changing an incidence value and the resulting projected effect on the cancer-specific mortality rates as shown in Fig. 5 . Although the focus of this paper was not on when or whether prostate cancer should be screened, one can see that it may take 5-10 years to see a favorable reduction in the cancer-specific mortality.
Likewise, whether or not to screen will in large part also depend on another highly sensitive value: how quickly Al lesions (taken as a group) progress. The current published series of Al lesions show a wide range in progression rates, Table 3 . There are undoubtedly different subsets at higher or lower risk for progression [84] which are important to identify in order to make the best decisions for an individual patient. Yet for the purpose of an epidemiological model such as ours, indeed for the purpose of screening the male population as a whole, we must know the progression probability of Al lesions considered as a group. The question then becomes: how representative are the Table 3 series to all patients with Al cancer? Since we cannot know this for certain from the literature, we can use the model's sensitivity analyses to define reasonable upper and lower values for Al progression rates, to project what the eventual cancer-specific mortality would be if a given rate is assumed. For example, a value of 0.01 seems too low for the annual probability of progression of an untreated Al to an A2 lesion in whites [PAlA2(w)], since when used in our model, the projected cancer-specific mortality rates were lower than the SEER data. (We would anticipate an untreated group of Al lesions would progress and ultimately yield higher cancer-specific mortality rates than the SEER which included treated patients.) In order to approximate the mortality rates in the SEER data, apAlA2(w) value of 0.015 is needed-but this would be a feasible value only if the treatment given to SEER patients had no effect. So values of 0.01 and 0.15 might be too low for what the "natural history" or "expectant management" of a group of Al lesions would be assuming treatment has a beneficial effect. To set a reasonable "upper limit", we used a pAlA2(w) of 0.04-which resulted in projected cancer-specific mortality rates twice that of SEER. This would be possible only if the treatment given to the SEER patients were 100% efficacious for one-half of all lesions. This is unlikely given that in the SEER data, 6065% of the lesions were considered "localized" at the time of diagnosis [85] and in the ACS paper, only about one-half of patients were in clinical A and B stages at the time of diagnosis [7] . In fact many of these are probably pathological Dl lesions [12] less amenable to cure. We therefore chose an "in-between" value of 0.02 for the pAlA in our baseline analysis for white men. This value seems plausible, yet leaves room for the possible effects of treatment.
Yet this value did not seem as appropriate for the African-American cohort. When we used 0.02 for the annual probability of progression of Al to A2 lesions in blacks [PAlA2(b)], we obtained cancer-specific mortality rates lower than the SEER data (Fig. 3) . As can be seen in the graph, we needed to use higher values for pAlA2(b) and pA1 B(b) to yield the appropriate increase in cancer-specific mortality rates compared to whites. This occurred even if we kept the progression rates for the remaining stages in our model the same as in whites, (consistent with the findings of Austin et al. [86] but different from the ACS study [87] where black patients in clinical stages B, C, and D fared worse). The fact that we had to use a different pA1 A2 value for whites and blacks in order to match the appropriate SEER curves, suggests that perhaps pathological Al lesions behave differently in the two races. This would support the theory that prostate cancer requires multiple steps in order to achieve biological activity [9, 77, 88] , although access to care may also play a role [88] . Our model is therefore useful to define "ballpark" ranges for feasible Al progression rates for the purpose of epidemiological projections. However we must again caution that these values seem appropriate when used together with our set of baseline incidences. If the model's pathological incidences are in fact erroneously low, then our "ballpark" values for Al progression would tend to be erroneously high. Nevertheless we believe the model is useful since it uses numbers compatible with those found in the literature, and rank orders the many parameters to show their relative impact on cancer-specific mortality.
Although our model has some potential applications, it also has some potential misapplications. The progression rates used in this model should not be used to predict the prognosis of individual patients, since tumor volume or grade which can be helpful in predicting progression [84], were not explicitly modeled. Our model could be made more complex to involve these subsets within the stages, but for this to occur, both the proportion of these subsets and their progression rates would need to be known.
Therefore the baseline transitional probabilities should not be used in the future as "historical controls" against which to measure the efficacy of a particular treatment. One might be tempted at this point to discuss further the implications of the sensitivity indices in Table 2 , such as the relative value of current therapies. However, we do not feel we should do this until the model is expanded to include quality of life adjustments [82] and cost issues. Although unfortunately we cannot yet answer many practical questions about screening and treatment for prostate cancer, we do not want to minimize this model's utility since it correlates the clinical literature with its epidemiological consequences in an explicit fashion [82] . Without such a correlation, the full public health consequences of various test/treatment strategies cannot be quantified if the only endpoint is a theoretical "Quality Adjusted Life Year", rather than the more practical "cancer-specific" and "overall" mortality rates.
In summary, this model correlates the clinical literature with the epidemiology of prostate cancer and can be used for further decision analyses. We recommend that future research be done to more precisely quantify the pathological incidence of prostate cancer in men under 5&60 years of age. More certainty is also needed before generalizing the results of relatively small Al series to millions of men, since Al progression rates critically affect the eventual cancer-specific mortality.
Enough uncertainty remains at this point however, that we cannot advocate widespread screening for prostate cancer until its merit be demonstrated either by the definitive long term study, or by examination of costs and quality-of-life-adjusted benefits.
